Results 31 to 40 of about 1,728,317 (301)

The Impact of Ankle Arthritis Treatment on Quality Adjusted Life Years

open access: yesFoot & Ankle Orthopaedics, 2017
Category: Ankle, Ankle Arthritis Introduction/Purpose: Patients living with end stage ankle arthritis suffer significant disability. They are two standard deviations below population scores for all symptom and function SF-36 sub-scales. In addition, they
Kelly Hynes MD, BSc   +5 more
doaj   +1 more source

Fundamental Measurement: The Need Fulfilment Quality of Life (N-QOL) Measure

open access: yesINNOVATIONS in Pharmacy, 2021
The quality adjusted life year (QALY) has serious problems related to its failure to adhere to measurement theory. If a QALY is to be meaningful, the utility score that translates time spent to an equivalent time spent in so-called perfect health must ...
Paul C. Langley, Stephen P. McKenna
doaj   +1 more source

How to allocate scarce health resources without discriminating against people with disabilities [PDF]

open access: yes, 2016
One widely used method for allocating health care resources involves the use of cost-effectiveness analysis (CEA) to rank treatments in terms of quality-adjusted life-years (QALYs) gained.
John, Tyler M.   +2 more
core   +1 more source

Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Retinoblastoma (RB) is the most common pediatric ocular cancer, yet population‐based data on survival and risk factors remain limited. This study aimed to describe survival in a large national RB cohort and identify predictors of death and complications.
Samuel Sassine   +14 more
wiley   +1 more source

Income-related inequality in life-years and quality-adjusted life-years [PDF]

open access: yesJournal of Health Economics, 2000
We estimate the income-related inequality in Sweden with respect to life-years and quality-adjusted life-years (QALYs). We use a large data set from Sweden with over 40,000 individuals followed up for 10-16 years, to estimate the survival and quality-adjusted survival in different income groups.
Gerdtham, Ulf-G., Johannesson, Magnus
openaire   +3 more sources

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis [PDF]

open access: yes, 2003
OBJECTIVE: To evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in the United Kingdom. DESIGN: Modelling cost effectiveness.
Abrams, K.   +6 more
core   +2 more sources

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács   +8 more
wiley   +1 more source

The Proposal and Application of Quality-adjusted Life Years

open access: yesYixue yu zhexue
Quality-adjusted life years (QALYs) is a quantitative health measure that integrates both life expectancy and quality, proposed in the 1970s as an effective tool for aiding the rational allocation of healthcare resources while balancing efficiency and ...
Yixuan LI
doaj   +1 more source

Measuring the impact of alcohol-related disorders on quality of life through general population preferences

open access: yesGaceta Sanitaria, 2017
Objective: To estimate the intangible effects of alcohol misuse on the drinker's quality of life, based on general population preferences Methods: The most important effects (dimensions) were identified by means of two focus groups conducted with ...
Eva Rodríguez-Míguez   +1 more
doaj   +1 more source

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy